Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984377 | 0.98 | LMNA (0.71) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL9314768 | 0.94 | LMNA (0.67) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL8024467 | 0.91 | LMNA (0.64) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL19332232 | 0.89 | LMNA (0.61) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL7524136 | 0.89 | MAOB (0.64) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL19346040 | 0.88 | LMNA (0.60) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL19332234 | 0.88 | LMNA (0.60) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL3176303 | 0.88 | LMNA (0.63) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL16280743 | 0.86 | LMNA (0.57) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL161867 | 0.85 | LMNA (0.56) | LMNAMEN1KMT2AHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110760565-A | Detection kit for paraoxonase 1 and preparation method thereof | 苏州普瑞斯生物科技有限公司 | 2020-02-07 | — | — | CN | claimed |
| CN-109402213-A | A kind of method that Enzymatic Resolution prepares (R) -1- (2- naphthalene) ethamine | 江苏理工学院 | 2019-03-01 | — | — | CN | claimed |
| CN-104744287-A | Actarit production method | CHU HAIYAN | 2015-07-01 | — | — | CN | claimed |
| CN-101650312-A | Method for detecting serum paraoxonase activity | HENAN INST ENGINEERING | 2010-02-17 | — | — | CN | claimed |
| US-5164515-A | Chemical compounds | WENDSTONE CHEMICALS PLC (GB) | 1992-11-17 | — | — | US | claimed |
| EP-0239354-A2 | 2,2-Dinitrophenylethane derivatives and their application as protecting compounds | Wendstone Chemicals P.L.C. (GB) | 1987-09-30 | — | — | EP | claimed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-12435181-B2 | Formulations capable of reacting with or removal of molecular oxygen | LI SHENSHEN (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250289785-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | MITOIMMUNE THERAPEUTICS INC. (KR) | 2025-09-18 | — | — | US | disclosed |
| EP-0003670-A1 | Preparation of alkyl 2-aryl acrylates | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1979-08-22 | — | — | EP | disclosed |
| US-4163788-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1979-08-07 | — | — | US | disclosed |
| US-4126691-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
| US-4081275-A | Photographic film units containing colorless para-nitrobenzylidene dye-forming compounds | EASTMAN KODAK COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-3997669-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3993763-A | ALPHA-(CYCLIC TERTIARY AMINO-PHENYL)-ALIPHATIC ACIDS | CIBA-GEIGY CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3936467-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289785-A1 | INDOLE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | AIFM2, AIFM1, HMOX1 | LMNA 1625/4885MEN1 813/4885KMT2A 4547/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | LMNA 1246/4885MEN1 2268/4885KMT2A 3301/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | LMNA 3163/4885MEN1 859/4885KMT2A 663/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | LMNA 1266/4885MEN1 2259/4885KMT2A 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.